Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Site 205, Brussels

Site 303, Amsterdam

Site 203, Leuven

Site 302, Nijmegen

Site 202, Haine-Saint-Paul

Site 501, Torino

Site 111, Marseille

Site 507, Milan

Site 707, Majadahonda

Site 705, Málaga

Site 107, Pessac

Site 108, Montpellier

Site 706, Santander

Site 701, Seville

Site 104, Nantes

Site 102, Angers

Site 405, Bonn

Site 404, Mainz

Site 103, Lille

Site 113, Lyon

Site 112, Paris

Site 101, Paris

Site 106, Amiens

Site 503, Palermo

Site 114, Clichy

Site 920, Fresno

Site 903, La Jolla

Site 911, Aurora

Site 912, Gainesville

Site 924, Atlanta

Site 917, Atlanta

Site 909, New Orleans

Site 921, Worcester

Site 902, Detroit

Site 927, New York

Site 908, Durham

Site 919, Philadelphia

Site 916, Memphis

Site 913, Fort Sam Houston

Site 923, Houston

Site 906, San Antonio

Site 931, Salt Lake City

Site 930, Charlottesville

Site 901, Richmond

Site 201, Edegem

Site 204, Ghent

Site 109, Nice

Site 504, Roma

Site 603, Bucharest

Site 601, Bucharest

Site 602, Bucharest

Site 703, Barcelona

Site 802, Camberley

Site 808, Hull

Site 801, Newcastle upon Tyne

Site 803, Nottingham